


CLAIMS

1. A compound of Formula I:



or a pharmaceutically acceptable salt thereof, wherein:

R^1 is selected from the group consisting of (4- to 10-membered)heterocycloalkyl, (C_6-C_{10}) aryl and (5- to 14-membered)heteroaryl, and, where chemically permissible, the (4- to 10-membered)heterocycloalkyl, (C_6-C_{10}) aryl and (5- to 14-membered)heteroaryl moieties are optionally substituted with one to five R^2 ;

when present, each R^2 is independently selected from the group consisting of halogen, oxo, cyano, hydroxy, $-SF_5$, nitro, optionally substituted (C_1-C_6) alkyl, optionally substituted (C_2-C_6) alkenyl, optionally substituted (C_2-C_6) alkynyl, optionally substituted (C_1-C_6) alkylthio, optionally substituted (C_1-C_6) alkoxy, $-N(R^4)(R^5)$, $-N(R^4)(C(=O)R^5)$, $-C(=O)N(R^4)(R^5)$, $-C(=O)-O-N(R^4)(R^5)$, $-C(=O)-R^4$, $-C(=O)-OR^4$, and optionally substituted (C_3-C_8) cycloalkyl;

when present, each R^3 is independently selected from the group consisting of halogen, cyano, hydroxy, $-SF_5$, nitro, optionally substituted (C_1-C_6) alkyl, optionally substituted (C_2-C_6) alkenyl, optionally substituted (C_2-C_6) alkynyl, optionally substituted (C_1-C_6) alkylthio, optionally substituted (C_1-C_6) alkoxy, $-N(R^4)(R^5)$, $-N(R^4)(C(=O)R^5)$, $-C(=O)N(R^4)(R^5)$, $-C(=O)-O-N(R^4)(R^5)$, $-C(=O)-R^4$, and $-C(=O)-OR^4$;

R^4 and R^5 are each independently selected from the group consisting of hydrogen and optionally substituted (C_1-C_6) alkyl;

R^6 and R^7 are each independently selected from the group consisting of hydrogen, optionally substituted (C_1-C_6) alkyl, $-(CH_2)_n-(C_3-C_8)$ cycloalkyl, $-(CH_2)_n$ -(4- to 10-membered) heterocycloalkyl, $-(CH_2)_n-(C_6-C_{10})$ aryl, and $-(CH_2)_n$ -(5- to 10-membered)heteroaryl, and where chemically permissible, the (C_3-C_8) cycloalkyl, (4- to 10-membered)heterocycloalkyl, (C_6-C_{10}) aryl, and (5- to 10-membered)heteroaryl are optionally substituted with one to five R^8 ; or

R^6 and R^7 taken together with the nitrogen to which they are attached form a (4- to 10-membered)heterocycloalkyl, and where chemically permissible, the (4- to 10-membered)-heterocycloalkyl is optionally substituted with one to five R^9 ;

when present, each R^8 is independently selected from the group consisting of halogen, oxo, cyano, hydroxy, $-SF_5$, nitro, optionally substituted (C_1-C_6) alkyl, optionally substituted (C_2-C_6) alkenyl, optionally substituted (C_2-C_6) alkynyl, optionally substituted (C_1-C_6) alkylthio, optionally substituted (C_1-C_6) alkoxy, $-N(R^4)(R^5)$, $-N(R^4)(C(=O)R^5)$, $-C(=O)N(R^4)(R^5)$, $-C(=O)-O-N(R^4)(R^5)$, $-C(=O)-R^4$, and $-C(=O)-OR^4$;

when present, each R^9 is independently selected from the group consisting of halogen, oxo, cyano, hydroxy, $-SF_5$, nitro, optionally substituted (C_1-C_6) alkyl, optionally substituted (C_2-C_6) alkenyl, optionally substituted (C_2-C_6) alkynyl, optionally substituted (C_1-C_6) alkylthio, optionally substituted (C_1-C_6) alkoxy, $-N(R^4)(R^5)$, $-N(R^4)(C(=O)R^5)$, $-C(=O)N(R^4)(R^5)$, $-C(=O)-O-N(R^4)(R^5)$, $-C(=O)-R^4$, and $-C(=O)-OR^4$;

b is represented by an integer selected from 0, 1, 2, or 3; and

n is represented by an integer selected from 0, 1, 2, 3 or 4.

2. The compound according to claim 1, or a pharmaceutically acceptable salt thereof, wherein R^1 is a (4- to 10-membered)heterocycloalkyl optionally substituted with one to three R^2 , wherein the optionally substituted heterocycloalkyl is selected from the group consisting of azetidiny, dihydrofuranyl, dihydrothiophenyl, tetrahydrothiophenyl, tetrahydrofuranyl, tetrahydrotriazinyl, tetrahydropyrazolyl, tetrahydrooxazinyl, tetrahydropyrimidinyl, octahydrobenzofuranyl, octahydrobenzimidazolyl, octahydrobenzothiazolyl, imidazolidinyl, pyrrolidinyl, piperidinyl, piperazinyl, oxazolidinyl, isothiazolidinyl, thiazolidinyl, pyrazolidinyl, thiomorpholinyl, tetrahydropyranyl, tetrahydrothiazinyl, tetrahydrothiadiazinyl, tetrahydrooxazolyl, morpholinyl, oxetanyl, tetrahydrodiazinyl, oxazinyl, oxathiazinyl, quinuclidinyl, chromanyl, isochromanyl, dihydrobenzodioxinyl, benzodioxolyl, benzoxazinyl, indolinyl, dihydrobenzofuranyl, tetrahydroquinolyl, isochromyl, dihydro-1*H*-isoindolyl, 2-azabicyclo[2.2.1]heptanonyl, 3-azabicyclo[3.1.0]hexanyl, and 3-azabicyclo[4.1.0]heptanyl.

3. The compound according to claim 1, or a pharmaceutically acceptable salt thereof, wherein R^1 is a (C_6-C_{10}) aryl optionally substituted with one to three R^2 , wherein the optionally substituted (C_6-C_{10}) aryl is phenyl or naphthyl.

4. The compound according to claim 3, or a pharmaceutically acceptable salt thereof, wherein the optionally substituted (C₆-C₁₀)aryl is phenyl.

5. The compound according to claim 1, or a pharmaceutically acceptable salt thereof, wherein R¹ is a (5- to 14-membered)heteroaryl optionally substituted with one to three R², wherein the optionally substituted (5- to 14-membered)heteroaryl is selected from the group consisting of triazolyl, imidazolyl, furanyl, isoxazolyl, isothiazolyl, 1,2,3-, 1,2,4, 1,2,5-, or 1,3,4-oxadiazolyl, oxazolyl, thiophenyl, thiazolyl, isothiazolyl, pyrazolyl, pyridinyl, pyrazinyl, pyrimidinyl, pyridazinyl, indolyl, indazolyl, benzofuranyl, benzimidazolyl, benzothienyl, benzoxadiazolyl, benzothiazolyl, isobenzothiofuranyl, benzothiofuranyl, benzisoxazolyl, benzoxazolyl, benzodioxolyl, furanopyridinyl, purinyl, imidazopyridinyl, imidazopyrimidinyl, pyrrolopyridinyl, pyrazolopyridinyl, pyrazolopyrimidinyl, thienopyridinyl, triazolopyrimidinyl, triazolopyridinyl, quinolinyl, isoquinolinyl, cinnolinyl, quinazolinyl, oxochromenyl, and 1,4-benzoxazinyl.

6. The compound according to claim 5, or a pharmaceutically acceptable salt thereof, wherein the heteroaryl is a (5- to 10-membered)nitrogen-containing heteroaryl selected from the group consisting of triazolyl, imidazolyl, pyrazolyl pyridinyl, pyrazinyl, pyrimidinyl, pyridazinyl, triazolopyridinyl, pyrazolopyridinyl, pyrazolopyrimidinyl, or quinoxalinyl.

7. The compound according to claim 6, or a pharmaceutically acceptable salt thereof, wherein the heteroaryl is selected from:

- i) a (5-membered)nitrogen-containing heteroaryl; or
- ii) a (6-membered)nitrogen-containing heteroaryl.

8. The compound according to any one of claims 1-7, or a pharmaceutically acceptable salt thereof, wherein each R² is independently selected from the group consisting of halogen, oxo, cyano, hydroxy, optionally substituted (C₁-C₆)alkyl, and optionally substituted (C₁-C₆)alkoxy.

9. The compound according to claim 8, or a pharmaceutically acceptable salt thereof, wherein R² is selected from:

- i) a halogen selected from fluoro or chloro;

ii) an optionally substituted (C₁-C₆)alkyl selected from methyl, ethyl or propyl, and the methyl, ethyl and propyl are optionally substituted with one to three fluorine atoms; or

iii) an optionally substituted (C₁-C₆)alkoxy selected from methoxy, ethoxy or propoxy and the methoxy, ethoxy and propoxy are optionally substituted with one to three fluorine atoms.

10. The compound according to any one of claims 1-9, or a pharmaceutically acceptable salt thereof, wherein R⁶ and R⁷ are each independently selected from the group consisting of hydrogen, optionally substituted (C₁-C₆)alkyl, -(CH₂)_n-(C₃-C₈)cycloalkyl, -(CH₂)_n-(C₆-C₁₀)aryl, and -(CH₂)_n-(5- to 6-membered)heteroaryl, and where chemically permissible, the (C₃-C₈)cycloalkyl, (C₆-C₁₀)aryl, and (5- to 6-membered)heteroaryl are optionally substituted with one to three R⁸; or

R⁶ and R⁷ taken together with the nitrogen to which they are attached form a (4- to 6-membered)heterocycloalkyl, and where chemically permissible, the (4- to 6-membered)-heterocycloalkyl is optionally substituted with one to three R⁹;

when present each R⁸ is independently selected from the group consisting of halogen, oxo, cyano, hydroxy, -SF₅, nitro, optionally substituted (C₁-C₆)alkyl, optionally substituted (C₂-C₆)alkenyl, optionally substituted (C₂-C₆)alkynyl, optionally substituted (C₁-C₆)alkylthio, optionally substituted (C₁-C₆)alkoxy, -N(R⁴)(R⁵), -N(R⁴)(C(=O)R⁵), -C(=O)N(R⁴)(R⁵), -C(=O)-O-N(R⁴)(R⁵), -C(=O)-R⁴, and -C(=O)-OR⁴; and

when present each R⁹ is independently selected from the group consisting of halogen, oxo, cyano, hydroxy, -SF₅, nitro, optionally substituted (C₁-C₆)alkyl, optionally substituted (C₂-C₆)alkenyl, optionally substituted (C₂-C₆)alkynyl, optionally substituted (C₁-C₆)alkylthio, optionally substituted (C₁-C₆)alkoxy, -N(R⁴)(R⁵), -N(R⁴)(C(=O)R⁵), -C(=O)N(R⁴)(R⁵), -C(=O)-O-N(R⁴)(R⁵), -C(=O)-R⁴, and -C(=O)-OR⁴.

11. The compound according to claim 10, or a pharmaceutically acceptable salt thereof, wherein one of R⁶ and R⁷ is hydrogen and the other is an optionally substituted (C₁-C₆)alkyl selected from the group consisting of methyl, ethyl, propyl, isopropyl, butyl, *tert*-butyl, pentyl and hexyl, and the methyl, ethyl, propyl, isopropyl, butyl, *tert*-butyl, pentyl and hexyl is optionally substituted with one or more fluorine atoms.

12. The compound according to claim 10, or a pharmaceutically acceptable salt thereof, wherein one of R⁶ and R⁷ is hydrogen and the other is -(CH₂)_n-(C₃-C₈)cycloalkyl selected from cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cyclooctyl or bicyclo[1.1.1]pentyl, wherein the cycloalkyl is optionally substituted with one to three R⁸.

13. The compound according to claim 10, or a pharmaceutically acceptable salt thereof, wherein one of R⁶ and R⁷ is hydrogen and the other is -(CH₂)_n-(C₆-C₁₀)aryl, wherein the aryl is optionally substituted with one to three R⁸.

14. The compound according to claim 10, or a pharmaceutically acceptable salt thereof, wherein one of R⁶ and R⁷ is hydrogen and the other is -(CH₂)_n-(5- to 6-membered)heteroaryl selected from triazolyl, imidazolyl, furanyl, isoxazolyl, isothiazolyl, 1,2,3-, 1,2,4-, 1,2,5-, or 1,3,4-oxadiazolyl, oxazolyl, thiophenyl, thiazolyl, isothiazolyl, pyrazolyl, pyridinyl, pyrazinyl, pyrimidinyl, or pyridazinyl, wherein the heteroaryl is optionally substituted with one to three R⁸.

15. The compound according to any one of claims 10-14, or a pharmaceutically acceptable salt thereof, wherein each R⁸ is independently selected from the group consisting of halogen, oxo, cyano, hydroxy, optionally substituted (C₁-C₆)alkyl, and optionally substituted (C₁-C₆)alkoxy.

16. The compound according to claim 10, or a pharmaceutically acceptable salt thereof, wherein R⁶ and R⁷ taken together with the nitrogen to which they are attached form a (4- to 6-membered)heterocycloalkyl optionally substituted with one to three R⁹, wherein the heterocycloalkyl is selected from azetidiny, tetrahydropyrazolyl, tetrahydrooxazinyl, tetrahydropyrimidinyl, imidazolidinyl, piperidinyl, piperazinyl, oxazolidinyl, or pyrrolidinyl.

17. The compound according to claim 16, or a pharmaceutically acceptable salt thereof, wherein the heterocycloalkyl is azetidiny.

18. The compound according to any one of claims 16-17, or a pharmaceutically acceptable salt thereof, wherein each R⁹ is independently selected from the group consisting of halogen, oxo, cyano, hydroxy, optionally substituted (C₁-C₆)alkyl, and optionally substituted (C₁-C₆)alkoxy.

19. The compound according to any one of claims 1-18, or a pharmaceutically acceptable salt thereof, wherein b is an integer selected from 0, 1 or 2 and, when present, each R³ is independently selected from the group consisting of halogen, cyano, hydroxy, -SF₅, nitro, optionally substituted (C₁-C₆)alkyl, and optionally substituted (C₁-C₆)alkoxy.

20. A compound selected from the group consisting of:

azetidin-1-yl[3-(4-chlorophenyl)imidazo[1,2-*b*]pyridazin-2-yl]methanone;
3-(4-chlorophenyl)-*N*-cyclopropylimidazo[1,2-*b*]pyridazine-2-carboxamide;
azetidin-1-yl[3-(3,5-difluoro-4-methoxyphenyl)imidazo[1,2-*b*]pyridazin-2-yl]methanone;
N-cyclopropyl-3-(2-methoxypyrimidin-5-yl)imidazo[1,2-*b*]pyridazine-2-carboxamide;
3-(6-cyanopyridin-3-yl)-*N*-cyclopropylimidazo[1,2-*b*]pyridazine-2-carboxamide;
N-cyclopropyl-3-([1,2,4]triazolo[1,5-*a*]pyridin-6-yl)imidazo[1,2-*b*]pyridazine-2-carboxamide;
3-(4-chloro-3-fluorophenyl)-*N*-(1-methyl-1*H*-pyrazol-4-yl)imidazo[1,2-*b*]pyridazine-2-carboxamide;
azetidin-1-yl[3-(pyrazolo[1,5-*a*]pyridin-6-yl)imidazo[1,2-*b*]pyridazin-2-yl]methanone;
3-(4-chloro-2,5-difluorophenyl)-*N*-cyclopropylimidazo[1,2-*b*]pyridazine-2-carboxamide;
3-(4-chloro-3-fluorophenyl)-*N*-cyclopropylimidazo[1,2-*b*]pyridazine-2-carboxamide;
N-cyclopropyl-3-(3,4-dichlorophenyl)imidazo[1,2-*b*]pyridazine-2-carboxamide;
3-(4-chloro-2-methylphenyl)-*N*-cyclopropylimidazo[1,2-*b*]pyridazine-2-carboxamide;
azetidin-1-yl[3-(4-chloro-3-fluorophenyl)imidazo[1,2-*b*]pyridazin-2-yl]methanone;
3-(5-chloropyridin-3-yl)-*N*-cyclopropylimidazo[1,2-*b*]pyridazine-2-carboxamide;
azetidin-1-yl[3-(5-chloropyridin-3-yl)imidazo[1,2-*b*]pyridazin-2-yl]methanone;
azetidin-1-yl[3-([1,2,4]triazolo[1,5-*a*]pyridin-6-yl)imidazo[1,2-*b*]pyridazin-2-yl]methanone;
3-(4-cyano-2-fluoro-5-methylphenyl)-*N*-cyclopropylimidazo[1,2-*b*]pyridazine-2-carboxamide;
4-[2-(azetidin-1-ylcarbonyl)imidazo[1,2-*b*]pyridazin-3-yl]-5-fluoro-2-methylbenzonitrile;
3-(4-cyano-5-fluoro-2-methylphenyl)-*N*-cyclopropylimidazo[1,2-*b*]pyridazine-2-carboxamide;
4-[2-(azetidin-1-ylcarbonyl)imidazo[1,2-*b*]pyridazin-3-yl]-2-fluoro-5-methylbenzonitrile;
3-(4-chloro-3-fluorophenyl)-*N*-cyclopropyl-*N*-methylimidazo[1,2-*b*]pyridazine-2-carboxamide;
N-cyclopropyl-3-(pyrazolo[1,5-*a*]pyridin-6-yl)imidazo[1,2-*b*]pyridazine-2-carboxamide;

4-[2-(azetidin-1-ylcarbonyl)imidazo[1,2-*b*]pyridazin-3-yl]-2-fluorobenzonitrile;
 4-[2-(azetidin-1-ylcarbonyl)imidazo[1,2-*b*]pyridazin-3-yl]-2,5-difluorobenzonitrile;
 3-(4-chloro-5-fluoro-2-methylphenyl)-*N*-methylimidazo[1,2-*b*]pyridazine-2-carboxamide;
 3-(4-chlorophenyl)-*N*-propylimidazo[1,2-*b*]pyridazine-2-carboxamide;
 [3-(4-chlorophenyl)imidazo[1,2-*b*]pyridazin-2-yl](pyrrolidin-1-yl)methanone;
 3-(3,5-dichlorophenyl)-*N*-propylimidazo[1,2-*b*]pyridazine-2-carboxamide;
 3-(4-chloro-3-fluorophenyl)-*N*-propylimidazo[1,2-*b*]pyridazine-2-carboxamide;
 3-(4-chlorophenyl)-*N*-(2-methylcyclopropyl)imidazo[1,2-*b*]pyridazine-2-carboxamide;
 [3-(4-chlorophenyl)imidazo[1,2-*b*]pyridazin-2-yl](3-methoxyazetidin-1-yl)methanone;
 3-(4-chlorophenyl)-*N*-cyclopropyl-*N*-methylimidazo[1,2-*b*]pyridazine-2-carboxamide;
 3-(4-chlorophenyl)-*N*-(1-methylcyclopropyl)imidazo[1,2-*b*]pyridazine-2-carboxamide;
 3-(3-chloro-5-fluorophenyl)-*N*-propylimidazo[1,2-*b*]pyridazine-2-carboxamide;
 3-(3-chloro-5-fluorophenyl)-*N*-cyclopropylimidazo[1,2-*b*]pyridazine-2-carboxamide;
 3-(3-chlorophenyl)-*N*-cyclopropylimidazo[1,2-*b*]pyridazine-2-carboxamide;
N-(bicyclo[1.1.1]pent-1-yl)-3-(4-chlorophenyl)imidazo[1,2-*b*]pyridazine-2-carboxamide;
N-cyclopropyl-3-(furo[3,2-*b*]pyridin-6-yl)imidazo[1,2-*b*]pyridazine-2-carboxamide;
 3-(1,3-benzoxazol-5-yl)-*N*-cyclopropylimidazo[1,2-*b*]pyridazine-2-carboxamide;
 3-(4-chloro-2-fluorophenyl)-*N*-cyclopropylimidazo[1,2-*b*]pyridazine-2-carboxamide;
N-cyclopropyl-3-(3-fluoro-4-methylphenyl)imidazo[1,2-*b*]pyridazine-2-carboxamide;
N-cyclopropyl-3-[2-(trifluoromethyl)pyridin-4-yl]imidazo[1,2-*b*]pyridazine-2-carboxamide;
 azetidin-1-yl{3-[2-(trifluoromethyl)pyridin-4-yl]imidazo[1,2-*b*]pyridazin-2-yl}methanone;
 3-(4-chloro-3-fluorophenyl)-*N*-(2,2-difluorocyclopropyl)imidazo[1,2-*b*]pyridazine-2-carboxamide;
 3-(4-chloro-3-fluorophenyl)-*N*-[(1*R*,2*S*)-2-fluorocyclopropyl]imidazo[1,2-*b*]pyridazine-2-carboxamide;
 3-(4-chlorophenyl)-*N*-[(1*R*,2*S*)-2-fluorocyclopropyl]imidazo[1,2-*b*]pyridazine-2-carboxamide;
 azetidin-1-yl[3-(4-chloro-3,5-difluorophenyl)imidazo[1,2-*b*]pyridazin-2-yl]methanone;
 3-(5-chloropyridin-3-yl)-*N*-propylimidazo[1,2-*b*]pyridazine-2-carboxamide;
 azetidin-1-yl[3-(3-chloro-4-methylphenyl)imidazo[1,2-*b*]pyridazin-2-yl]methanone;
 azetidin-1-yl[3-(2,3-dihydro-1-benzofuran-5-yl)imidazo[1,2-*b*]pyridazin-2-yl]methanone;
 azetidin-1-yl[3-(4-chloro-3-methylphenyl)imidazo[1,2-*b*]pyridazin-2-yl]methanone;
 azetidin-1-yl[3-(4-chloro-2-fluorophenyl)imidazo[1,2-*b*]pyridazin-2-yl]methanone;
 azetidin-1-yl[3-(4-fluoro-3,5-dimethylphenyl)imidazo[1,2-*b*]pyridazin-2-yl]methanone;
 azetidin-1-yl[3-(2-fluoro-4-methylphenyl)imidazo[1,2-*b*]pyridazin-2-yl]methanone;

azetidin-1-yl[3-(3-fluoro-4-methoxyphenyl)imidazo[1,2-*b*]pyridazin-2-yl]methanone;
 azetidin-1-yl[3-(4-chloro-2-methylphenyl)imidazo[1,2-*b*]pyridazin-2-yl]methanone
 [3-(4-chlorophenyl)imidazo[1,2-*b*]pyridazin-2-yl](3-fluoroazetidin-1-yl)methanone;
 [3-(4-chlorophenyl)imidazo[1,2-*b*]pyridazin-2-yl](3,3-difluoroazetidin-1-yl)methanone;
 azetidin-1-yl[3-(5-chloro-2-methylphenyl)imidazo[1,2-*b*]pyridazin-2-yl]methanone;
 azetidin-1-yl[3-(2,4-dichlorophenyl)imidazo[1,2-*b*]pyridazin-2-yl]methanone;
 3-(4-chloro-2-fluorophenyl)-*N*-[(1*R*,2*S*)-2-fluorocyclopropyl]imidazo[1,2-*b*]pyridazine-2-
 carboxamide;
 3-(5-chloropyridin-3-yl)-*N*-[(1*R*,2*S*)-2-fluorocyclopropyl]imidazo[1,2-*b*]pyridazine-2-
 carboxamide;
 3-(4-chloro-2-methylphenyl)-*N*-[(1*R*,2*S*)-2-fluorocyclopropyl]imidazo[1,2-*b*]pyridazine-2-
 carboxamide;
 3-(3-chloro-4-methylphenyl)-*N*-[(1*R*,2*S*)-2-fluorocyclopropyl]imidazo[1,2-*b*]pyridazine-2-
 carboxamide;
N-[(1*R*,2*S*)-2-fluorocyclopropyl]-3-(2-fluoro-4-methylphenyl)imidazo[1,2-*b*]pyridazine-2-
 carboxamide;
 azetidin-1-yl[3-(2-fluoro-4-methoxyphenyl)imidazo[1,2-*b*]pyridazin-2-yl]methanone;
 azetidin-1-yl[3-(pyrazolo[1,5-*a*]pyrimidin-6-yl)imidazo[1,2-*b*]pyridazin-2-yl]methanone;
N-cyclopropyl-3-[2-(difluoromethoxy)pyridin-4-yl]imidazo[1,2-*b*]pyridazine-2-
 carboxamide;
 azetidin-1-yl{3-[2-(difluoromethoxy)pyridin-4-yl]imidazo[1,2-*b*]pyridazin-2-yl}methanone;
 azetidin-1-yl[3-(1,3-benzoxazol-6-yl)imidazo[1,2-*b*]pyridazin-2-yl]methanone;
N-cyclopropyl-3-(pyrazolo[1,5-*a*]pyrimidin-6-yl)imidazo[1,2-*b*]pyridazine-2-carboxamide;
 3-(4-cyano-2-fluorophenyl)-*N*-cyclopropylimidazo[1,2-*b*]pyridazine-2-carboxamide;
 3-(5-cyano-2-methylphenyl)-*N*-cyclopropylimidazo[1,2-*b*]pyridazine-2-carboxamide;
 3-(4-chloro-3-fluorophenyl)-*N*-ethylimidazo[1,2-*b*]pyridazine-2-carboxamide;
 3-(4-chloro-3-fluorophenyl)-*N*-(1*H*-pyrazol-4-yl)imidazo[1,2-*b*]pyridazine-2-carboxamide;
 azetidin-1-yl[3-(3,4-dichlorophenyl)imidazo[1,2-*b*]pyridazin-2-yl]methanone;
 azetidin-1-yl[3-(3-chlorophenyl)imidazo[1,2-*b*]pyridazin-2-yl]methanone;
 3-(4-chlorophenyl)-*N*-ethylimidazo[1,2-*b*]pyridazine-2-carboxamide;
 azetidin-1-yl[3-(2,2-difluoro-1,3-benzodioxol-5-yl)imidazo[1,2-*b*]pyridazin-2-
 yl]methanone;
N-cyclopropyl-3-[6-(difluoromethoxy)pyridin-3-yl]imidazo[1,2-*b*]pyridazine-2-
 carboxamide;
 3-(1,3-benzoxazol-6-yl)-*N*-cyclopropylimidazo[1,2-*b*]pyridazine-2-carboxamide;

N-cyclopropyl-3-(7-methyl[1,2,4]triazolo[1,5-*a*]pyridin-6-yl)imidazo[1,2-*b*]pyridazine-2-carboxamide;
 3-(4-cyano-3-fluorophenyl)-*N*-cyclopropylimidazo[1,2-*b*]pyridazine-2-carboxamide;
 azetidin-1-yl[3-(4-chloro-2,5-difluorophenyl)imidazo[1,2-*b*]pyridazin-2-yl]methanone;
 3-(4-cyano-2,5-difluorophenyl)-*N*-cyclopropylimidazo[1,2-*b*]pyridazine-2-carboxamide;
 3-(4-chloro-2,5-difluorophenyl)-*N*-methylimidazo[1,2-*b*]pyridazine-2-carboxamide;
 3-(4-chloro-3-fluorophenyl)-*N*-methylimidazo[1,2-*b*]pyridazine-2-carboxamide;
 3-(4-chloro-2-methylphenyl)-*N*-ethylimidazo[1,2-*b*]pyridazine-2-carboxamide;
 3-(4-chloro-2,5-difluorophenyl)-*N*-ethylimidazo[1,2-*b*]pyridazine-2-carboxamide;
 3-(4-chloro-5-fluoro-2-methylphenyl)-*N*-(propan-2-yl)imidazo[1,2-*b*]pyridazine-2-carboxamide;
 3-(4-cyano-5-fluoro-2-methylphenyl)-*N*-ethylimidazo[1,2-*b*]pyridazine-2-carboxamide;
 3-(4-cyano-5-fluoro-2-methylphenyl)-*N*-(propan-2-yl)imidazo[1,2-*b*]pyridazine-2-carboxamide;
 3-(4-chloro-2,5-difluorophenyl)-*N*-(propan-2-yl)imidazo[1,2-*b*]pyridazine-2-carboxamide;
 3-(4-chlorophenyl)-*N*-(pyrimidin-2-yl)imidazo[1,2-*b*]pyridazine-2-carboxamide;
 3-(4-chlorophenyl)-*N*-(cyclopropylmethyl)imidazo[1,2-*b*]pyridazine-2-carboxamide;
 3-(4-chlorophenyl)-*N*-(1*H*-pyrazol-5-yl)imidazo[1,2-*b*]pyridazine-2-carboxamide; and
 3-(4-chloro-3,5-difluorophenyl)-*N*-cyclopropylimidazo[1,2-*b*]pyridazine-2-carboxamide;
 or a pharmaceutically acceptable salt thereof.

21. A compound selected from the group consisting of:

azetidin-1-yl[3-(3-chloro-2,4-dimethylphenyl)imidazo[1,2-*b*]pyridazin-2-yl]methanone, formate salt;
 azetidin-1-yl[3-(2,3-dihydro-1,4-benzodioxin-6-yl)imidazo[1,2-*b*]pyridazin-2-yl]methanone, formate salt;
 azetidin-1-yl[3-(quinoxalin-6-yl)imidazo[1,2-*b*]pyridazin-2-yl]methanone, formate salt;
 1-{3-[2-(azetidin-1-ylcarbonyl)imidazo[1,2-*b*]pyridazin-3-yl]-4-fluorophenyl}ethanone, formate salt;
 3-(4-chlorophenyl)-*N*-[2-(2-hydroxyphenyl)ethyl]imidazo[1,2-*b*]pyridazine-2-carboxamide, formate salt;
 3-(4-chlorophenyl)-*N*-(5-methyl-1,2-oxazol-3-yl)imidazo[1,2-*b*]pyridazine-2-carboxamide, trifluoroacetate salt; and
 3-(4-chlorophenyl)-*N*-(2-methyl-2*H*-1,2,3-triazol-4-yl)imidazo[1,2-*b*]pyridazine-2-carboxamide, trifluoroacetate salt.

22. A pharmaceutical composition comprising the compound according to any one of claims 1-21, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient.

23. A compound of Formula I, or a pharmaceutically acceptable salt thereof, as defined in any one of claims 1 to 21, for use in treating a patient suffering from a disease or condition mediated by the PDE4B isoform, wherein said disease or condition is selected from schizophrenia, depression, anxiety, Alzheimer's disease, Parkinson's disease, multiple sclerosis, chronic obstructive pulmonary disease, inflammation, stroke, asthma, cerebral vascular disease, and allergic conjunctivitis.

24. A compound of Formula I, or a pharmaceutically acceptable salt thereof, as defined in any one of claims 1 to 21, for use in treating a central nervous system (CNS), neuroinflammatory, autoimmune, or inflammatory disease or disorder.

25. A compound of claim 24 or a pharmaceutically acceptable salt thereof, for use in treating a central nervous system (CNS) disease or disorder.